Patents by Inventor Lex M. Cowsert

Lex M. Cowsert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense inhibition of fra-1 expression
    Patent number: 6124133
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fra-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fra-1. Methods of using these compounds for modulation of fra-1 expression and for treatment of diseases associated with expression of fra-1 are provided.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: September 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Jennifer K. Taylor, Lex M. Cowsert
  • Antisense modulation of SHP-1 expression
    Patent number: 6121047
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SHP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SHP-1. Methods of using these compounds for modulation of SHP-1 expression and for treatment of diseases associated with expression of SHP-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: September 19, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense oligonucleotide inhibition of ras
    Patent number: 6117848
    Abstract: Compositions and methods are provided for the modulation of ras expression. Oligonucleotides are provided which are targeted to nucleic acids encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions associated with ras are also disclosed.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: September 12, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Muthiah Manoharan
  • Antisense inhibition of G-alpha-S1 expression
    Patent number: 6110664
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-S1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-S1. Methods of using these compounds for modulation of G-alpha-S1 expression and for treatment of diseases associated with expression of G-alpha-S1 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: August 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of G-alpha-16 expression
    Patent number: 6107091
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-16. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-16. Methods of using these compounds for modulation of G-alpha-16 expression and for treatment of diseases associated with expression of G-alpha-16 are provided.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: August 22, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense modulation of SRA expression
    Patent number: 6107092
    Abstract: Antisense compounds, compositions and methods are provided for modulating the function or amount of SRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to SRA or nucleic acids encoding SRA. Methods of using these compounds for modulation of SRA levels and for treatment of diseases associated with SRA are provided.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: August 22, 2000
    Assignees: Isis Pharmaceuticals Inc., Baylor College of Medicine
    Inventors: Lex M. Cowsert, C. Frank Bennett, Bert W. O'Malley
  • Antisense inhibition of PI3K p85 expression
    Patent number: 6100090
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3K p85. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3K p85. Methods of using these compounds for modulation of PI3K p85 expression and for treatment of diseases associated with expression of PI3K p85 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: August 8, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of human mek1 expression
    Patent number: 6096543
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEK1. Methods of using these compounds for modulation of MEK1 expression and for treatment of diseases associated with expression of MEK1 are provided.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: August 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of X-linked inhibitor of apoptosis expression
    Patent number: 6087173
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of X-linked inhibitor of apoptosis. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding X-linked inhibitor of apoptosis. Methods of using these compounds for modulation of X-linked inhibitor of apoptosis expression and for treatment of diseases associated with expression of X-linked inhibitor of apoptosis are provided.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: July 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Lex M. Cowsert
  • Antisense modulation of MEKK5 expression
    Patent number: 6080546
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK5. Methods of using these compounds for modulation of MEKK5 expression and for treatment of diseases associated with expression of MEKK5 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: June 27, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William Gaarde, Lex M. Cowsert
  • Antisense modulation of Survivin expression
    Patent number: 6077709
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: June 20, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Eric E. Swayze, Lex M. Cowsert
  • Antisense modulation of TRADD expression
    Patent number: 6077672
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TRADD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TRADD. Methods of using these compounds for modulation of TRADD expression and for treatment of diseases associated with expression of TRADD are provided.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: June 20, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of NF-kappa-B p65 subunit expression
    Patent number: 6069008
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p65 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding NF-kappa-B p65 subunit. Methods of using these compounds for modulation of NF-kappa-B p65 subunit expression and for treatment of diseases associated with expression of NF-kappa-B p65 subunit are provided.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: May 30, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Beta catenin expression
    Patent number: 6066500
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Beta catenin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Beta catenin. Methods of using these compounds for modulation of Beta catenin expression and for treatment of diseases associated with expression of Beta catenin are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: May 23, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense inhibition of G-alpha-i3 expression
    Patent number: 6063626
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i3. Methods of using these compounds for modulation of G-alpha-i3 expression and for treatment of diseases associated with expression of G-alpha-i3 are provided.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: May 16, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of Jun N-terminal Kinase Kinase-2 expression
    Patent number: 6054440
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-2. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-2 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-2 are provided.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: April 25, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of ETs-2 expression
    Patent number: 6054316
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ets-2. The compositions comprise antisense com ounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ets-2. Methods of using these compounds for modulation of Ets-2 expression and for treatment of diseases associated with expression of Ets-2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 25, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Antisense modulation of MDMX expression
    Patent number: 6046320
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MDMX. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MDMX. Methods of using these compounds for modulation of MDMX expression and for treatment of diseases associated with expression of MDMX are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: April 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of G-alpha-i1 expression
    Patent number: 6046321
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i1. Methods of using these compounds for modulation of G-alpha-i1 expression and for treatment of diseases associated with expression of G-alpha-i1 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: April 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense modulation of PI3 kinase p110 delta expression
    Patent number: 6046049
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 delta. Methods of using these compounds for modulation of PI3 kinase p110 delta expression and for treatment of diseases associated with expression of PI3 kinase p110 delta are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: April 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert